John Clarke has a 30 year record of early-stage venture capital investment success. John co-founded Cardinal Partners in 1997 and currently serves as a Managing Partner of the firm. John leads Cardinal’s life sciences investment efforts and has had an extraordinary record of success. John led the firm’s investment in Cubist Pharmaceuticals (Nasdaq:CBST – 3x return/6 mos.), Momenta Pharmaceuticals (Nasdaq:MNTA – 8x return/4 yrs.), Alnylam Pharmaceuticals (Nasdaq:ALNY – 4x return/4 yrs.) and Sirtris Pharmaceuticals (Nasdaq:SIRT – acquired by GSK – 6x return/4 yrs.). John also spearheaded Cardinal’s investment in and served as a director for: TechRx Corporation (acquired by NDCHealth/4x return) and Visicu (Nasdaq:EICU – acquired by Phillips Electronics/11x return). John currently serves on the Board of Directors for Cardinal portfolio companies Abide Therapeutics, aTyr Pharma, Rib-X Pharmaceuticals (observer) and Verastem, as well as Alnylam Pharmaceuticals and Momenta Pharmaceuticals.John entered the ve

 John Clarke has a 30 year record of early-stage venture capital investment success. John co-founded Cardinal Partners in 1997 and currently serves as a Managing Partner of the firm. John leads Cardinal’s life sciences investment efforts and has had an extraordinary record of success. John led the firm’s investment in Cubist Pharmaceuticals (Nasdaq:CBST – 3x return/6 mos.), Momenta Pharmaceuticals (Nasdaq:MNTA – 8x return/4 yrs.), Alnylam Pharmaceuticals (Nasdaq:ALNY – 4x return/4 yrs.) and Sirtris Pharmaceuticals (Nasdaq:SIRT – acquired by GSK – 6x return/4 yrs.). John also spearheaded Cardinal’s investment in and served as a director for: TechRx Corporation (acquired by NDCHealth/4x return) and Visicu (Nasdaq:EICU – acquired by Phillips Electronics/11x return). John currently serves on the Board of Directors for Cardinal portfolio companies Abide Therapeutics, aTyr Pharma, Rib-X Pharmaceuticals (observer) and Verastem, as well as Alnylam Pharmaceuticals and Momenta Pharmaceuticals.John entered the ve